What is CJC-1295? CJC-1295 is a synthetic analogue of growth hormone releasing hormone, usually shortened to GHRH. Published studies examine how an albumin-binding version influences growth hormone and insulin-like growth factor 1, or IGF-1. Its molecular design helps explain why it behaves differently from shorter-acting GHRH fragments. [1]
The useful starting point is the exact molecule. Names such as CJC-1295, CJC-1295 with DAC, and CJC-1295 without DAC can appear together online, but a finding about one preparation should not automatically be assigned to another.
This guide accompanies Azzurri's CJC-1295 with DAC product page. It explains the published experiments, the measurements they used, and the questions those measurements leave open.
How does CJC-1295 relate to growth hormone?
GHRH is a signaling peptide that interacts with receptors on growth hormone producing cells in the pituitary. A GHRH analogue is designed to act through that signaling system. It is a different substance from growth hormone itself.
Early CJC-1295 work examined modified GHRH fragments attached to albumin, a blood protein. The investigators tested biological activity in cultured rat pituitary cells and then examined hormone responses in rats. This was an important step in characterizing the molecule, but it was not a study of human exercise performance. [1]
For background on this distinction, Azzurri's guide to peptide receptor binding explains how a molecular interaction connects to a measured response.
What does DAC mean in CJC-1295?
DAC refers to a drug affinity complex. In this context, it describes the albumin-binding modification associated with the long-acting form. The original development paper describes a reactive group that allows the modified peptide to form a covalent bond with albumin. [1]
A covalent bond is a chemical attachment. This detail matters because the albumin-associated molecule has different persistence from an unmodified GHRH fragment. The design changes how scientists interpret exposure over time.
Think of the name as an identification task. Before comparing two descriptions, check whether both identify the same modification. Matching the first part of a name is not enough to establish that the underlying preparations are equivalent.
CJC-1295 with DAC vs without DAC: why the distinction matters
The well-known human studies discussed below concern the long-acting, albumin-binding CJC-1295 preparation. Their results should remain attached to that preparation. A product described as without DAC does not acquire the same evidence simply because CJC-1295 appears in its name. [2]
A useful comparison records the full compound description, molecular identity, study formulation, and measured endpoint. If one of those details is missing, the comparison is incomplete.
This is especially relevant when a short online description combines a half-life from one paper with a product name from another source. Two individually accurate details can create an inaccurate overall impression when their contexts differ.
What have CJC-1295 human studies measured?
A 2006 publication reported two randomized, double-blind, placebo-controlled trials in healthy adults. The trials lasted 28 and 49 days. Investigators measured CJC-1295 exposure alongside growth hormone and IGF-1 responses. They observed sustained increases in the hormone measurements under the tested conditions. [2]
These are endocrine findings. They do not directly establish improvements in strength, endurance, sleep quality, or everyday recovery. Those outcomes would need to be measured with appropriate methods in studies designed around those questions.
When checking a claim, read the outcome measures before reading the conclusion. A trial can be carefully conducted while answering a narrower question than the headline attached to it.
What does preserved growth hormone pulsatility mean?
Growth hormone secretion varies over time. A separate 2006 study examined this pattern using frequent overnight blood samples from healthy men before exposure and one week afterward. Pulsatile secretion remained detectable, while trough and average growth hormone levels increased. Pulse frequency and magnitude were not significantly changed. [3]
This finding does not mean the entire hormone profile stayed unchanged. Preserved pulses and an elevated baseline can occur together. Describing only the pulses would leave out part of the result.
It also illustrates why a single blood sample and a series of samples answer different questions. One gives a snapshot. Repeated measurements allow investigators to examine the pattern behind that snapshot. Neither automatically describes how a participant feels or functions.
What does CJC-1295 half-life actually describe?
The healthy-adult trials estimated a half-life of approximately 5.8 to 8.1 days for the studied preparation. This is a pharmacokinetic measurement describing the decline in measured concentrations. It is not a timetable for a promised benefit. [2]
A half-life cannot, by itself, establish how long a downstream response persists. It also cannot show whether a particular response is desirable for an individual.
When someone quotes a duration, ask what was measured: the compound, a hormone, or a clinical outcome. Keeping those categories separate avoids turning a concentration measurement into a personal expectation.
Azzurri's peptide half-life explainer introduces the terminology. The original study remains the place to verify which preparation and population produced a quoted figure.
Why have scientists examined blood protein changes?
A 2009 study analyzed serum samples from 11 healthy young men before and one week after CJC-1295 exposure. Using protein separation and mass spectrometry, investigators identified changes in several protein spots and considered whether these could serve as markers of GH or IGF-1 activity. [4]
The work explored possible biomarkers. It did not establish that the changed proteins represented better health, improved recovery, or a useful screening test for everyone.
A proposed biomarker needs further evaluation. Readers should ask whether the measurement is reproducible, whether it changes for other reasons, and whether it predicts an outcome that matters. Finding a measurable change is the beginning of that process.
Do the findings establish muscle growth or fat loss?
The studies summarized here do not establish those outcomes. Hormone concentrations, secretion patterns, and serum protein profiles are different endpoints from muscle strength or changes in body fat.
A helpful way to assess a benefit statement is to rewrite it as a testable question. For example, did participants perform better on a specified strength test, compared with a suitable control group, over a defined period? If the paper only reports hormone measurements, it has not answered that question.
The same reasoning applies to combinations. Evidence about one compound does not automatically establish the effects of a blend. A combination introduces another set of questions about exposure, interactions, and outcomes.
What should readers know about safety and product information?
The early healthy-adult trials reported no serious adverse reactions during their observation periods. That finding is limited by the participants, study duration, and conditions tested. It cannot rule out uncommon events or establish long-term safety. [2]
Changes involving hormone signaling deserve an individualized clinical assessment. A published average cannot account for someone's medical history, other medicines, or reasons for a particular laboratory result.
On the CJC-1295 with DAC listing, compare the complete compound name with the study being cited. Product identification and analytical documentation address different questions from clinical effectiveness. A purity result cannot substitute for a human outcome study.
Study sources
- Jetté and colleagues, 2005. Albumin-linked GHRH analogues in cell and rat experiments. PubMed, PMID 15817669.
- Teichman and colleagues, 2006. CJC-1295 pharmacokinetics and hormone responses in healthy adults. PubMed, PMID 16352683.
- Ionescu and Frohman, 2006. Growth hormone secretion patterns during CJC-1295 exposure. PubMed, PMID 17018654.
- Sackmann-Sala and colleagues, 2009. Serum protein measurements following CJC-1295 exposure. PubMed, PMID 19386527.
Frequently asked questions
What is CJC-1295?
It is a synthetic GHRH analogue. The albumin-binding form discussed here has been studied for its effects on growth hormone and IGF-1 measurements.
Is CJC-1295 the same as growth hormone?
No. CJC-1295 acts through a hormone signaling pathway. Growth hormone is one of the substances measured when scientists investigate the response.
What does DAC change?
The albumin-binding modification changes the molecule's persistence. This is why a study of the DAC-associated form should not be treated as evidence for every similarly named preparation.
Does a longer half-life mean better results?
No. Persistence and benefit are separate questions. A longer measurable exposure does not establish improved function or suitability for an individual.
Have CJC-1295 human studies been published?
Yes. The examples here examine hormone responses, secretion patterns, and protein measurements. Their findings should be interpreted within those specific aims.
What should I check before trusting a CJC-1295 claim?
Check the exact preparation, participant group, comparison, measured outcome, and observation period. Then ask whether the claim describes the actual result or goes beyond it.